{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"Incidence of adverse events(AE) as assessed by CTCAE version 5.0","groups":[{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years","id":"OG000","title":"Placebo Combine With Chemotherapy"},{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years","id":"OG001","title":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From date of consent informed until 60 days after the last investigational product administration. Up to 2 approximately years","title":"Number of Participants Experiencing an Adverse Event(AE)","type":"SECONDARY","unitOfMeasure":"Participants"}